The maker of the EpiPen device is considering a significant shift that could ultimately lead to a sale of the company or certain assets. Pharmaceutical giant Mylan said Wednesday that it is forming a committee to weigh “a wide range of alternatives to unlock the true value” of the company.


Read More At Article Source | Article Attribution